China SXT Pharmaceuticals (SXTC) Total Debt Growth (1y) (2019 - 2026)
China SXT Pharmaceuticals (SXTC) Total Debt Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -3.69% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 37.49% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -2.48% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 4.38% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -6.91% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 41.53% |
| 10 | China SXT Pharmaceuticals | 31,562.64 | -28.14 Mn | - | 25.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 851.56% |
| Sep 30, 2025 | -90.51% |
| Mar 31, 2025 | -82.78% |
| Sep 30, 2024 | 627.36% |
| Mar 31, 2024 | 113.86% |
| Sep 30, 2023 | -90.68% |
| Mar 31, 2023 | -74.84% |
| Sep 30, 2022 | -43.04% |
| Mar 31, 2022 | -95.33% |
| Sep 30, 2021 | 3,373.10% |
| Mar 31, 2021 | 263.73% |
| Sep 30, 2020 | -96.77% |
| Mar 31, 2020 | 164.57% |
| Sep 30, 2019 | 819.89% |